NA Acute Respiratory Distress Syndrome (ARDS) Treatment Market

TABLE OF CONTENTS

1 INTRODUCTION 16

• 1.1 OBJECTIVES OF THE STUDY 16
• 1.2 MARKET DEFINITION 16
• 1.3 OVERVIEW OF NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 16
• 1.4 LIMITATIONS 18
• 1.5 MARKETS COVERED 18

2 MARKET SEGMENTATION 20

• 2.1 MARKETS COVERED 20
• 2.2 GEOGRAPHICAL SCOPE 21
• 2.3 YEARS CONSIDERED FOR THE STUDY 22
• 2.4 CURRENCY AND PRICING 22
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
• 2.6 MULTIVARIATE MODELLING 26
• 2.7 TYPE LIFELINE CURVE 26
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
• 2.9 DBMR MARKET POSITION GRID 28
• 2.10 MARKET END USER COVERAGE GRID 29
• 2.11 VENDOR SHARE ANALYSIS 30
• 2.12 SECONDARY SOURCES 31
• 2.13 ASSUMPTIONS 31

3 EXECUTIVE SUMMARY 32

4 PREMIUM INSIGHTS 35

• 4.1 PESTEL ANALYSIS 36
• 4.2 PORTER'S FIVE FORCES 37
• 4.3 INSURANCE REIMBURSEMENT 38
  • 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 38
  • 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 38
  • 4.3.3 ABBOTT CODING GUIDE FOR ECMO 39
  • 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 39
  • 4.3.5 CERN HEALTH INSURANCE SCHEME 40
  • 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 40
  • 4.3.7 AMERICAN HOSPITAL ASSOCIATION 41
• 4.4 PIPELINE ANALYSIS 42
• 4.5 PRICING ANALYSIS 44

5 MARKET OVERVIEW 45

• 5.1 DRIVERS 47
  • 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 47
  • 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 47
  • 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 48
  • 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 48
• 5.2 RESTRAINTS 49
  • 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 49
  • 5.2.2 HIGH COST OF DEVICES AND TREATMENT 49
• 5.3 OPPORTUNITIES 50
  • 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 50
  • 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 50
  • 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 51
• 5.4 CHALLENGES 52
  • 5.4.1 STRINGENT RULES & REGULATIONS 52
  • 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 53

6 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 54

• 6.1 OVERVIEW 55
• 6.2 MECHANICAL VENTILATION 58
  • 6.2.1 HIGH-FLOW NASAL O2 59
  • 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 59
  • 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 59
  • 6.2.4 PRONE POSITION VENTILATION 59
  • 6.2.5 OTHERS 60
• 6.3 CORTICOSTEROIDS 60
  • 6.3.1 METHYLPREDNISOLONE 61
  • 6.3.2 DEXAMETHASONE 61
  • 6.3.3 OTHERS 61
• 6.4 ANTIVIRAL MEDICATION 62
  • 6.4.1 RIBAVIRIN 63
  • 6.4.2 OSELTAMIVIR 63
  • 6.4.3 OTHERS 63
• 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 63
• 6.6 TOCILIZUMAB 64
• 6.7 OTHERS 64

7 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 65

• 7.1 OVERVIEW 66
• 7.2 SEPSIS 69
• 7.3 INHALATION OF HARMFUL SUBSTANCES 69
• 7.4 SEVERE PNEUMONIA 70
• 7.5 OTHERS 70

8 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 71

• 8.1 OVERVIEW 72
• 8.2 PARENTERAL 75
  • 8.2.1 INTRAVENOUS 75
  • 8.2.2 INTRAMUSCULAR 75
• 8.3 ORAL 76
• 8.4 OTHERS 76

9 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 77

• 9.1 OVERVIEW 78
• 9.2 HOSPITALS 81
• 9.3 SPECIALTY CLINICS 81
• 9.4 HOME HEALTHCARE 82
• 9.5 OTHERS 82

10 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 83

• 10.1 OVERVIEW 84
• 10.2 DIRECT TENDER 87
• 10.3 HOSPITAL PHARMACY 87
• 10.4 RETAIL PHARMACY 88
• 10.5 ONLINE PHARMACY 88

11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 89

• 11.1 NORTH AMERICA 91
  • 11.1.1 U.S. 96
  • 11.1.2 CANADA 101
  • 11.1.3 MEXICO 106

12 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 111

• 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 111

13 SWOT ANALYSIS 112

14 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 113

• 14.1 GILEAD SCIENCES INC. 113
  • 14.1.1 COMPANY SNAPSHOT 113
  • 14.1.2 REVENUE ANALYSIS 114
  • 14.1.3 COMPANY SHARE ANALYSIS 114
  • 14.1.4 PRODUCT PORTFOLIO 115
  • 14.1.5 RECENT DEVELOPMENT 115
• 14.2 TERUMO CORPORATION 116
  • 14.2.1 COMPANY SNAPSHOT 116
  • 14.2.2 REVENUE ANALYSIS 116
  • 14.2.3 COMPANY SHARE ANALYSIS 117
  • 14.2.4 PRODUCT PORTFOLIO 117
  • 14.2.5 RECENT DEVELOPMENT 117
• 14.3 GETINGE 118
  • 14.3.1 COMPANY SNAPSHOT 118
  • 14.3.2 REVENUE ANALYSIS 118
  • 14.3.3 COMPANY SHARE ANALYSIS 119
  • 14.3.4 PRODUCT PORTFOLIO 119
  • 14.3.5 RECENT DEVELOPMENT 119
• 14.4 LIVANOVA PLC 120
  • 14.4.1 COMPANY SNAPSHOT 120
  • 14.4.2 REVENUE ANALYSIS 120
  • 14.4.3 COMPANY SHARE ANALYSIS 121
  • 14.4.4 PRODUCT PORTFOLIO 121
  • 14.4.5 RECENT DEVELOPMENTS 121
• 14.5 MEDTRONIC 122
  • 14.5.1 COMPANY SNAPSHOT 122
  • 14.5.2 REVENUE ANALYSIS 122
  • 14.5.3 COMPANY SHARE ANALYSIS 123
  • 14.5.4 PRODUCT PORTFOLIO 123
  • 14.5.5 RECENT DEVELOPMENTS 123

• 14.6 ARMSTRONG MEDICAL 124
  • 14.6.1 COMPANY SNAPSHOT 124
  • 14.6.2 PRODUCT PORTFOLIO 124
  • 14.6.3 RECENT DEVELOPMENT 124
• 14.7 BESMED HEALTH BUSINESS CORP. 125
  • 14.7.1 COMPANY SNAPSHOT 125
  • 14.7.2 PRODUCT PORTFOLIO 125
  • 14.7.3 RECENT DEVELOPMENTS 126
• 14.8 DRAGERWERK AG & CO. KGAA 127
  • 14.8.1 COMPANY SNAPSHOT 127
  • 14.8.2 REVENUE ANALYSIS 127
  • 14.8.3 PRODUCT PORTFOLIO 128
  • 14.8.4 RECENT DEVELOPMENTS 128
• 14.9 EUROSETS 129
  • 14.9.1 COMPANY SNAPSHOT 129
  • 14.9.2 PRODUCT PORTFOLIO 129
  • 14.9.3 RECENT DEVELOPMENT 129
• 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 130
  • 14.10.1 COMPANY SNAPSHOT 130
  • 14.10.2 REVENUE ANALYSIS 130
  • 14.10.3 PRODUCT PORTFOLIO 131
  • 14.10.4 RECENT DEVELOPMENTS 131
• 14.11 FRESENIUS SE & CO. KGAA. 132
  • 14.11.1 COMPANY SNAPSHOT 132
  • 14.11.2 REVENUE ANALYSIS 132
  • 14.11.3 PRODUCT PORTFOLIO 133
  • 14.11.4 RECENT DEVELOPMENT 133
• 14.12 HAMILTON MEDICAL 134
  • 14.12.1 COMPANY SNAPSHOT 134
  • 14.12.2 PRODUCT PORTFOLIO 134
  • 14.12.3 RECENT DEVELOPMENT 134
• 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 135
  • 14.13.1 COMPANY SNAPSHOT 135
  • 14.13.2 PRODUCT PORTFOLIO 135
  • 14.13.3 RECENT DEVELOPMENT 135
• 14.14 NIPRO 136
  • 14.14.1 COMPANY SNAPSHOT 136
  • 14.14.2 REVENUE ANALYSIS 136
  • 14.14.3 PRODUCT PORTFOLIO 137
  • 14.14.4 RECENT DEVELOPMENT 137
• 14.15 PFIZER INC. 138
  • 14.15.1 COMPANY SNAPSHOT 138
  • 14.15.2 REVENUE ANALYSIS 138
  • 14.15.3 PRODUCT PORTFOLIO 139
  • 14.15.4 RECENT DEVELOPMENT 139
• 14.16 RESMED 140
  • 14.16.1 COMPANY SNAPSHOT 140
  • 14.16.2 REVENUE ANALYSIS 140
  • 14.16.3 PRODUCT PORTFOLIO 141
  • 14.16.4 RECENT DEVELOPMENT 141
• 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 142
  • 14.17.1 COMPANY SNAPSHOT 142
  • 14.17.2 PRODUCT PORTFOLIO 142
  • 14.17.3 RECENT DEVELOPMENT 142

15 QUESTIONNAIRE 143

16 RELATED REPORTS 146

LIST OF TABLES

• TABLE 1 LIST OF PRICES FOR APPROVED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT 44
• TABLE 2 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 57
• TABLE 3 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 58
• TABLE 4 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 58
• TABLE 5 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 59
• TABLE 6 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 59
• TABLE 7 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 60
• TABLE 8 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 60
• TABLE 9 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 61
• TABLE 10 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 61
• TABLE 11 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 62
• TABLE 12 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 62
• TABLE 13 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 62
• TABLE 14 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 62
• TABLE 15 NORTH AMERICA EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 63
• TABLE 16 NORTH AMERICA TOCILIZUMAB IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
• TABLE 17 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
• TABLE 18 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 68
• TABLE 19 NORTH AMERICA SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
• TABLE 20 NORTH AMERICA INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
• TABLE 21 NORTH AMERICA SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
• TABLE 22 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
• TABLE 23 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 74
• TABLE 24 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
• TABLE 25 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 75
• TABLE 26 NORTH AMERICA ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
• TABLE 27 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
• TABLE 28 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 80
• TABLE 29 NORTH AMERICA HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 81
• TABLE 30 NORTH AMERICA SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
• TABLE 31 NORTH AMERICA HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
• TABLE 32 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
• TABLE 33 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 86
• TABLE 34 NORTH AMERICA DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
• TABLE 35 NORTH AMERICA HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
• TABLE 36 NORTH AMERICA RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
• TABLE 37 NORTH AMERICA ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
• TABLE 38 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 91
• TABLE 39 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 91
• TABLE 40 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 92
• TABLE 41 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 92
• TABLE 42 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 92
• TABLE 43 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 93
• TABLE 44 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 93
• TABLE 45 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 93
• TABLE 46 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 93
• TABLE 47 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 94
• TABLE 48 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 94
• TABLE 49 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 94
• TABLE 50 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
• TABLE 51 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
• TABLE 52 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
• TABLE 53 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 97
• TABLE 54 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 97
• TABLE 55 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 97
• TABLE 56 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 98
• TABLE 57 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 98
• TABLE 58 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 98
• TABLE 59 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 98
• TABLE 60 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 99
• TABLE 61 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 99
• TABLE 62 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 99
• TABLE 63 U.S. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 100
• TABLE 64 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 100
• TABLE 65 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 100
• TABLE 66 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
• TABLE 67 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
• TABLE 68 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 102
• TABLE 69 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 102
• TABLE 70 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 102
• TABLE 71 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 103
• TABLE 72 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 103
• TABLE 73 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 103
• TABLE 74 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 103
• TABLE 75 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 104
• TABLE 76 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 104
• TABLE 77 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 104
• TABLE 78 CANADA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 105
• TABLE 79 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 105
• TABLE 80 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 105
• TABLE 81 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
• TABLE 82 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
• TABLE 83 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 107
• TABLE 84 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 107
• TABLE 85 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 107
• TABLE 86 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 107
• TABLE 87 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 108
• TABLE 88 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 108
• TABLE 89 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 108
• TABLE 90 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 108
• TABLE 91 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 109
• TABLE 92 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 109
• TABLE 93 MEXICO PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 109
• TABLE 94 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 110
• TABLE 95 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 110

LIST OF FIGURES

• FIGURE 1 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 20
• FIGURE 2 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION 23
• FIGURE 3 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS 24
• FIGURE 4 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 25
• FIGURE 5 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS 25
• FIGURE 6 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS 27
• FIGURE 7 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID 28
• FIGURE 8 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID 29
• FIGURE 9 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS 30
• FIGURE 10 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 34
• FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY ARE EXPECTED TO DRIVE THE NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2030 35
• FIGURE 12 MECHANICAL VENTILATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030 35
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 46
• FIGURE 14 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2022 55
• FIGURE 15 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 56
• FIGURE 16 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 56
• FIGURE 17 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, LIFELINE CURVE 57
• FIGURE 18 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2022 66
• FIGURE 19 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2023-2030 (USD THOUSAND) 67
• FIGURE 20 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, CAGR (2023-2030) 67
• FIGURE 21 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, LIFELINE CURVE 68
• FIGURE 22 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 72
• FIGURE 23 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 73
• FIGURE 24 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 73
• FIGURE 25 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 74
• FIGURE 26 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2022 78
• FIGURE 27 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 79
• FIGURE 28 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, CAGR (2023-2030) 79
• FIGURE 29 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, LIFELINE CURVE 80
• FIGURE 30 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 84
• FIGURE 31 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 85
• FIGURE 32 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 85
• FIGURE 33 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 86
• FIGURE 34 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: SNAPSHOT (2022) 90
• FIGURE 35 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%) 111